Websites of Interest
The Bridging Interventional Development Gaps (BrIDGs) program, formerly known as NIH-RAID, assists researchers in advancing promising therapeutic agents through late-stage preclinical development and into clinical testing.
The National Cancer Institute (NCI) Chemical Biology Consortium (CBC) was established to facilitate the discovery and development of new agents to treat cancer.
Therapeutics for Rare and Neglected Disease (TRND) is an effort to encourage and speed the development of new drugs for rare and neglected diseases.
NIH Psychoactive Drug Screening Program provides screening of novel psychoactive compounds for pharmacological and functional activity.
The Developmental Therapeutics Program (DTP) at NCI has comprehensive repositories which contain chemicals from synthetics, natural products, radiolabeled materials, biologics reference standards and reagents, tumor Repository for use by researchers.
The goals of the program include the identification of novel targets (genes or molecules) for therapeutic intervention, characterization of the behavioral effects of psychoactive agents, and design and development of novel ligands for functional brain imaging in humans, psychoactive agents for basic and clinical research, and potential therapeutic agents for the treatment of mental disorders.
Comprises of three repositories (Biosample, Data and Genetic samples) enable scientists not involved in the original studies to test new hypotheses without any new data or biospecimen collection.
DTP contain thousands of molecular readouts (RNA measurements, mutation status and enzymatic activity) which have been measured in the NCI panel of 60 human tumor cell lines with data available.